Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin
American Journal of Gastroenterology, Volume 103, No. 10, Year 2008
Notification
URL copied to clipboard!
Description
OBJECTIVES: Low-dose aspirin is standard treatment for prevention of cardiovascular events in at-risk patients. However, long-term administration of low-dose aspirin is associated with a greater risk of adverse events, including gastroduodenal ulcers. This study determined the efficacy of esomeprazole for reducing the risk of gastric and/or duodenal ulcers and dyspeptic symptoms in patients receiving continuous, low-dose aspirin therapy. METHODS: Patients aged ≥60 yr, without baseline gastroduodenal ulcer at endoscopy, who were receiving aspirin 75-325 mg once daily, were randomized to esomeprazole 20 mg once daily or placebo for 26 wk. The presence of endoscopic gastric and/or duodenal ulcers and esophageal lesions was assessed at weeks 8 and 26. Upper gastrointestinal symptoms were assessed at weeks 8, 16, and 26. RESULTS: The intention-to-treat population comprised 991 patients (esomeprazole, N = 493; placebo, N = 498). Twenty-seven patients (5.4%) in the placebo group developed a gastric or duodenal ulcer during 26 weeks' treatment compared with eight patients (1.6%) in the esomeprazole group (life-table estimates: 6.2% vs 1.8%; P = 0.0007). At 26 wk, the cumulative proportion of patients with erosive esophagitis was significantly lower for esomeprazole versus placebo (4.4% and 18.3%, respectively; P < 0.0001). At 26 wk, esomeprazole-treated patients were more likely to experience resolution of heartburn, acid regurgitation, and epigastric pain (P < 0.05). CONCLUSIONS: Esomeprazole 20 mg once daily reduces the risk of developing gastric and/or duodenal ulcers and symptoms associated with the continuous use of low-dose aspirin in patients aged ≥60 yr without preexisting gastroduodenal ulcers. © 2008 by Am. Coll. of Gastroenterology.
Authors & Co-Authors
Yeomans, Neville D.
Australia, Penrith
Western Sydney University
Lanas, Ángel I.
Spain, Zaragoza
Hospital Clinico Universitario Lozano Blesa
Labenz, Joachim
Germany, Siegen
Ev. Jung-stilling-krankenhaus Ggmbh
Veldhuyzen van Zanten, Sander
Canada, Halifax
Dalhousie University
van Rensburg, Christoffel Johannes
South Africa, Tygerberg
Tygerberg Hospital
István, Rácz
Hungary, Gyor
Petz Aladár County and Teaching Hospital
Tchernev, Konstantin Georgiev
Bulgaria, Sofia
University Hospital Alexandrovska
Karamanolis, Dimitrios Georgios
Greece, Athens
Evagelismos Hospital
Roda, Enrico
Italy, Bologna
Irccs Azienda Ospedaliero-universitaria Di Bologna
Hawkey, Christopher John
United Kingdom, Nottingham
Wolfson Digestive Diseases Centre
Nauclér, Emma C.
Sweden, Sodertalje
Astrazeneca Sweden
Svedberg, Lars Erik
Sweden, Sodertalje
Astrazeneca Sweden
Statistics
Citations: 204
Authors: 12
Affiliations: 11
Identifiers
Doi:
10.1111/j.1572-0241.2008.01995.x
e-ISSN:
15720241
Research Areas
Noncommunicable Diseases
Study Design
Cross Sectional Study